Inhibitor Therapeutics Inc. logo

Inhibitor Therapeutics Inc. (INTI)

Market Closed
2 Jun, 20:00
OTCQB OTCQB
OTCQB OTCQB Primary
PSX PSX
$
0. 0840
-0.001
-1.18%
$
14.67M Market Cap
- P/E Ratio
- Div Yield
1,200 Volume
0 Eps
$ 0.085
Previous Close
Add Transaction
Day Range
0.077 0.084
Year Range
0.035 0.124
Want to track INTI and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Get Started For Free

Summary

INTI closed yesterday lower at $0.08, a decrease of -1.18% from Monday's close, completing a monthly decrease of -6.67% or -$0.01. Over the past 12 months, INTI stock gained 78.72%.
INTI is not paying dividends to its shareholders.
The last earnings report, released on May 12, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on OTCQB (USD).

INTI Chart

No Data

People also search for

TLTFF
Theralase Technologies Inc.
$ 0.17
+5.63%
CLCS
Cell Source Inc.
$ 0.77
-3.75%
TELIF
Telescope Innovations Corp.
$ 0.61
+12.19%
RDGL
Vivos Inc.
$ 0.06
-0.41%
SDEV
Security Devices International, Inc.
$ 1.16
+0.87%

Inhibitor Therapeutics Inc. (INTI) FAQ

What is the stock price today?

The current price is $0.0840.

On which exchange is it traded?

Inhibitor Therapeutics Inc. is listed on OTCQB.

What is its stock symbol?

The ticker symbol is INTI.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 14.67M.

Has Inhibitor Therapeutics Inc. ever had a stock split?

No, there has never been a stock split.

Inhibitor Therapeutics Inc. Profile

Biotechnology Industry
Healthcare Sector
Francis E. O'Donnell Jr. CEO
OTCQB Exchange
45720M105 CUSIP
US Country
3 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Inhibitor Therapeutics, Inc. is a pharmaceutical development company focused on the creation and commercialization of therapies for patients dealing with certain types of cancer and non-cancerous proliferation disorders in the United States. Originally known as HedgePath Pharmaceuticals, Inc., the company underwent a name change to Inhibitor Therapeutics, Inc. in August 2019. Since its establishment in 1992, the company has rooted its operations in Tampa, Florida, dedicating its efforts to the development of innovative treatments for devastating diseases like prostate and lung cancer.

Products and Services

  • SUBA-Itraconazole for Prostate and Lung Cancer:

    • This is an oral formulation of the drug itraconazole, which has been tailored by Inhibitor Therapeutics for the treatment of prostate and lung cancer. It represents a significant part of the company's pipeline and showcases their commitment to advancing therapeutic options for cancer patients.

  • Phase 2b Study of SUBA-Itraconazole for Basal Cell Carcinoma Nevus Syndrome:

    • The company has achieved a positive outcome in the Phase 2b study of SUBA-Itraconazole, targeting the treatment of basal cell carcinoma nevus syndrome. This demonstrates Inhibitor Therapeutics’ capability in conducting successful clinical research and development endeavors aimed at addressing specific cancerous conditions.

Contact Information

Address: 900 W Platt St, Suite 200 Tampa, FL 33606, USA
Phone: 888 841 6811
Download app banner
Blog Affiliate Program About Terms Privacy Help Contact Us
2026 © Marketlog. All Rights Reserved.
Play store app banner Play store app banner dark App store app banner App store app banner dark